{"nctId":"NCT00575588","briefTitle":"52-week add-on to Metformin Comparison of Saxagliptin and Sulphonylurea, With a 52-week Extension Period","startDateStruct":{"date":"2007-12"},"conditions":["Type 2 Diabetes"],"count":891,"armGroups":[{"label":"Saxagliptin","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Saxagliptin"]},{"label":"Glipizide","type":"EXPERIMENTAL","interventionNames":["Drug: Metformin","Drug: Sulphonylurea"]}],"interventions":[{"name":"Metformin","otherNames":[]},{"name":"Sulphonylurea","otherNames":[]},{"name":"Saxagliptin","otherNames":["Onglyza"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosed with type 2 diabetes,\n* Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks prior to Visit 1,\n* HbA1c \\>6.5% and â‰¤10.0%\n\nExclusion Criteria:\n\n* Type 1 diabetes,\n* history of diabetic ketoacidosis or hyperosmolar non-ketonic coma,\n* Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Hemoglobin A1c (HbA1c) Change From Baseline to Week 52","description":"Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Per Protocol Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 52 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.46","spread":"0.045"},{"groupId":"OG001","value":"7.53","spread":"0.045"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.74","spread":"0.042"},{"groupId":"OG001","value":"6.71","spread":"0.042"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.74","spread":"0.038"},{"groupId":"OG001","value":"-0.80","spread":"0.038"}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 52 Weeks","description":"Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 52 weeks (Safety Analysis Set)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"36.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Body Weight Change From Baseline to Week 52","description":"Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 52 (Safety Analysis Set). Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 52 (LOCF) value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":"0.91"},{"groupId":"OG001","value":"88.6","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.6","spread":"0.90"},{"groupId":"OG001","value":"89.7","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":"0.17"},{"groupId":"OG001","value":"1.1","spread":"0.17"}]}]}]},{"type":"SECONDARY","title":"Mean Slope of the Regressions of Change From Week 24 to Week 52 in HbA1c","description":"Mean slopes of regression of change from Week 24 to Week 52 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Per Protocol Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.001","spread":"0.001"},{"groupId":"OG001","value":"0.004","spread":"0.001"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hemoglobin A1c (HbA1c) Change From Baseline to Week 104","description":"Adjusted mean change from baseline in HbA1c achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104 (Full Analysis Set). HbA1c is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.65","spread":"0.044"},{"groupId":"OG001","value":"7.65","spread":"0.041"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.27","spread":"0.050"},{"groupId":"OG001","value":"7.27","spread":"0.046"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.41","spread":"0.041"},{"groupId":"OG001","value":"-0.35","spread":"0.043"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Proportion of Participants Reporting at Least One Episode of Any Hypoglycaemic Event Over 104 Weeks","description":"Proportion of participants reporting at least one episode of any hypoglycaemic event for saxagliptin added on to metformin versus glipizide added on to metformin over 104 weeks (Safety Analysis Set)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":null},{"groupId":"OG001","value":"38.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Body Weight Change From Baseline to Week 104","description":"Adjusted mean change from baseline in Body Weight achieved with saxagliptin added on to metformin versus glipizide added on to metformin at Week 104. Body Weight is a continuous measure, the change from baseline for each participant is calculated as the Week 104 value minus the baseline value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.69","spread":"0.905"},{"groupId":"OG001","value":"88.57","spread":"0.955"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"87.47","spread":"0.898"},{"groupId":"OG001","value":"89.80","spread":"0.987"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.47","spread":"0.200"},{"groupId":"OG001","value":"1.29","spread":"0.205"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Mean Slope of the Regressions of Change From Week 24 to Week 104 in HbA1c","description":"Mean slopes of regression of change from Week 24 to Week 104 in HbA1c for saxagliptin added on to metformin versus glipizide added on to metformin (Full Analysis Set) achieved by fitting a mixed model with subject specific slopes for the time effect (weeks on randomized treatment was utilized). This analysis gives an assessment of the durability of the HbA1c effect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0041","spread":"0.0005"},{"groupId":"OG001","value":"0.0076","spread":"0.0005"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":54,"n":428},"commonTop":["Hypoglycaemia","Nasopharyngitis","Hypertension","Diarrhoea","Upper Respiratory Tract Infection"]}}}